Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease : A Multicenter Retrospective Study
BACKGROUND: Treatment of rheumatoid arthritis (RA)-related interstitial lung disease (ILD) is challenging, and many conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) have been associated with ILD development or progression. The aim of this multicentric retrospective study was to analyze the evolution of ILD in Italian RA-ILD patients treated with abatacept (ABA).
METHODS: All RA-ILD patients treated with ABA for at least six months were retrospectively evaluated. Serology, previous and concurrent therapies, chest high-resolution computer tomography (HRCT), forced vital capacity (FVC), and lung diffusion of carbon monoxide (CO, DLCO) were collected.
RESULTS: Forty-four patients were included; HRCT, FVC, and DLCO were analyzed at baseline, at one year, and at the end of follow-up. A remission or a low disease activity of RA was reached in 41/44 patients. Overall, FVC and DLCO remained stable or increased in 86.1% and 91.7% of patients, respectively, while HRCT was stable or improved in 81.4% of them. Previous and concurrent treatments, in particular, methotrexate, serology, age, sex, joint and lung disease duration were not associated with the outcome at univariate analysis.
CONCLUSION: The management of RA-ILD patients remains a critical unmet medical need. Waiting for prospective controlled studies, ABA has shown a good safety profile in our cohort of Italian RA-ILD patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 9(2020), 1 vom: 19. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cassone, Giulia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Abatacept |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm9010277 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM305612948 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305612948 | ||
| 003 | DE-627 | ||
| 005 | 20231225121549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm9010277 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1018.xml |
| 035 | |a (DE-627)NLM305612948 | ||
| 035 | |a (NLM)31963908 | ||
| 035 | |a (PII)E277 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cassone, Giulia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease |b A Multicenter Retrospective Study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: Treatment of rheumatoid arthritis (RA)-related interstitial lung disease (ILD) is challenging, and many conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) have been associated with ILD development or progression. The aim of this multicentric retrospective study was to analyze the evolution of ILD in Italian RA-ILD patients treated with abatacept (ABA) | ||
| 520 | |a METHODS: All RA-ILD patients treated with ABA for at least six months were retrospectively evaluated. Serology, previous and concurrent therapies, chest high-resolution computer tomography (HRCT), forced vital capacity (FVC), and lung diffusion of carbon monoxide (CO, DLCO) were collected | ||
| 520 | |a RESULTS: Forty-four patients were included; HRCT, FVC, and DLCO were analyzed at baseline, at one year, and at the end of follow-up. A remission or a low disease activity of RA was reached in 41/44 patients. Overall, FVC and DLCO remained stable or increased in 86.1% and 91.7% of patients, respectively, while HRCT was stable or improved in 81.4% of them. Previous and concurrent treatments, in particular, methotrexate, serology, age, sex, joint and lung disease duration were not associated with the outcome at univariate analysis | ||
| 520 | |a CONCLUSION: The management of RA-ILD patients remains a critical unmet medical need. Waiting for prospective controlled studies, ABA has shown a good safety profile in our cohort of Italian RA-ILD patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a abatacept | |
| 650 | 4 | |a interstitial lung disease | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a therapy | |
| 700 | 1 | |a Manfredi, Andreina |e verfasserin |4 aut | |
| 700 | 1 | |a Atzeni, Fabiola |e verfasserin |4 aut | |
| 700 | 1 | |a Venerito, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Vacchi, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Picerno, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Furini, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Erre, Gian Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Tomietto, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Fedele, Anna Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Della Casa, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Nucera, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Giannitti, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Sebastiani, Marco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 9(2020), 1 vom: 19. Jan. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g number:1 |g day:19 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm9010277 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 |e 1 |b 19 |c 01 | ||